The Molecular Mechanism of HIF-2α-Mediated ADRN-MES Phenotypic Transition Under Hypoxia in Neuroblastoma Cells
DOI:
https://doi.org/10.54097/1g98vq31Keywords:
Neuroblastoma, Hypoxia, Cytoplasmic Redistribution, HIF-2α.Abstract
Neuroblastomas are usually located in an area with poor oxygen supply inside the tumour; such an environment may promote metastasis and other serious behaviour in children. Tumor cells can switch between adrenergic and mesenchymal states to affect the clinical outcomes of young children.Hypoxia causes changes in the shape of cancer cells, the whole molecular signal pathway is still not known, and essential regulators that control these switches at different stages of cell growth have not been identified, Therefore,many crucial regulatory circuits still need to be studied. Based on the data of hypoxic cell lines, genetic knockdown assays and various molecular diagnostic methods were used to identify the metabolic pathways that cause structural changes in neuroblastoma under oxygen deprivation. HIF-2α is a switch that changes the expression pattern of the adrenergic signature genes into a mesenchymal one. PRRX1 and NOTCH3 are the secondary mediators that can decrease the production of native adrenergic mRNAs and promote the activation of a pro-tumorigenic mesenchymal feedback loop via HIF-2α. Currently, all of them are still at the level of laboratory cell culture and have not been validated by living mouse experiments or histopathological tests of real human tumour tissue. In the future, new technologies and a new biological model of rodents will be introduced into clinical trials to further verify the application of this model and enhance the development of HIF-2α-targeted drugs. This research provides a clear molecular basis for follow-up experimental exploration.
Downloads
References
[1] Durbin AD, Versteeg R. Cell state plasticity in neuroblastoma. European Journal of Paediatric Oncology, 2024, 4: 100184. DOI: https://doi.org/10.1016/j.ejcped.2024.100184
[2] Liao C, Liu X, Zhang C, Zhang Q. Tumor hypoxia: from basic knowledge to therapeutic implications. Seminars in Cancer Biology, 2023, 88: 172-186. DOI: https://doi.org/10.1016/j.semcancer.2022.12.011
[3] Chaves GS, Chennakesavalu M, Moore K, Adams H, Chittenden C, Wilkinson E, Vayani O, Kaufman ME, Chlenski A, He C, Cohn SL, Applebaum MA. Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma. Clinical and Translational Science, 2026, 19(3): e70508. DOI: https://doi.org/10.1111/cts.70508
[4] Påhlman S, Mohlin S. Hypoxia and hypoxia-inducible factors in neuroblastoma. Cell and Tissue Researc, 2018, 372(2): 269-275. DOI: https://doi.org/10.1007/s00441-017-2701-1
[5] Noguera R, Fredlund E, Piqueras M, Pietras A, Beckman S, Navarro S, Påhlman S. HIF-1α and HIF-2α are differentially regulated in vivo in neuroblastoma: high HIF-1α correlates negatively to advanced clinical stage and tumor vascularization. Clinical Cancer Research, 2009, 15(23): 7130-7136. DOI: https://doi.org/10.1158/1078-0432.CCR-09-0223
[6] van Groningen T, Akogul N, Westerhout EM, Chan A, Hasselt NE, Zwijnenburg DA, Broekmans M, Stroeken P, Haneveld F, Hooijer GKJ, Savci-Heijink CD, Lakeman A, Volckmann R, van Sluis P, Valentijn LJ, Koster J, Versteeg R, van Nes J. A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma. Nature Communications, 2019, 10(1): 1530. DOI: https://doi.org/10.1038/s41467-019-09470-w
[7] Sehgal M, Nayak SP, Sahoo S, Somarelli JA, Jolly MK. Mutually exclusive teams-like patterns of gene regulation characterize phenotypic heterogeneity along the noradrenergic-mesenchymal axis in neuroblastoma. Cancer Biology and Therapy, 2024, 25(1): 2301802. DOI: https://doi.org/10.1080/15384047.2024.2301802
[8] Patel AG, Ashenberg O, Collins NB, Segerstolpe Å, Jiang S, Slyper M, Huang X, Caraccio C, Jin H, Sheppard H, Xu K, Chang TC, Orr BA, Shirinifard A, Chapple RH, Shen A, Clay MR, Tatevossian RG, Reilly C, Patel J, Lupo M, Cline C, Dionne D, Porter CBM, Waldman J, Bai Y, Zhu B, Barrera I, Murray E, Vigneau S, Napolitano S, Wakiro I, Wu J, Grimaldi G, Dellostritto L, Helvie K, Rotem A, Lako A, Cullen N, Pfaff KL, Karlström Å, Jané-Valbuena J, Todres E, Thorner A, Geeleher P, Rodig SJ, Zhou X, Stewart E, Johnson BE, Wu G, Chen F, Yu J, Goltsov Y, Nolan GP, Rozenblatt-Rosen O, Regev A, Dyer MA. A spatial cell atlas of neuroblastoma reveals developmental, epigenetic and spatial axis of tumor heterogeneity. bioRxiv, 2024, 10802404. DOI: https://doi.org/10.1101/2024.01.07.574538
[9] Shi Y, Gilkes DM. HIF-1 and HIF-2 in cancer: structure, regulation, and therapeutic prospects. Cellular and Molecular Life Sciences, 2025, 82(1): 44. DOI: https://doi.org/10.1007/s00018-024-05537-0
[10] Cowman SJ, Koh MY. Revisiting the HIF switch in the tumor and its immune microenvironment. Trends in Cancer, 2022, 8(1): 28-42. DOI: https://doi.org/10.1016/j.trecan.2021.10.004
[11] Rioja P, Rey-Cardenas M, De Velasco G. Targeting HIF-2α and anemia: a therapeutic breakthrough for clear-cell renal cell carcinoma. Cancer Treatment Reviews, 2024, 129: 102801. DOI: https://doi.org/10.1016/j.ctrv.2024.102801
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

